The Epidemiology of Clostridium difficile Infection Inside and Outside Health Care Institutions

Infectious Disease Clinics of North America

Volumn 29, Issue 1, 2015, Pages 37-50

  Gerding, Dale N ^a,b   Lessa, Fernanda C ^c  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Clostridium difficile infection; Community associated; Health care associated; Risk factors; Strain type

Indexed keywords

ALBUMIN; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; PROTON PUMP INHIBITOR; VANCOMYCIN;

ALBUMIN BLOOD LEVEL; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CASE CONTROL STUDY; CAUSE OF DEATH; CLOSTRIDIUM DIFFICILE INFECTION; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; FECES ANALYSIS; GASTROSTOMY; GENE SEQUENCE; HEALTH SURVEY; HEALTHCARE ASSOCIATED INFECTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTESTINE FLORA; JEJUNOSTOMY; LEUKOCYTE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR EPIDEMIOLOGY; MOLECULAR TYPING; MORTALITY; NEOPLASM; NONHUMAN; OBESITY; ORGAN TRANSPLANTATION; PEPTOCLOSTRIDIUM DIFFICILE; PNEUMATOSIS INTESTINALIS; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDY; PULSED FIELD GEL ELECTROPHORESIS; RECURRENCE RISK; RESTRICTION MAPPING; REVIEW; RISK FACTOR; STOP CODON; VARIABLE NUMBER OF TANDEM REPEAT; WARD; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; GASTROINTESTINAL DISEASES; HEALTH CARE FACILITY; MICROBIOLOGY; TRANSMISSION; VIRULENCE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; GASTROINTESTINAL DISEASES; HEALTH FACILITIES; HUMANS; INCIDENCE; RISK FACTORS; VIRULENCE;

EID: 84922940698     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.11.004     Document Type: Review

References (87)

1. al Saif N., Brazier J.S. The distribution of Clostridium difficile in the environment of South Wales. JMed Microbiol 1996, 45:133-137.
2. Eckert C., Burghoffer B., Barbut F. Contamination of ready-to-eat raw vegetables with Clostridium difficile in France. JMed Microbiol 2013, 62(Pt 9):1435-1438.
3. Pasquale V., Romano V., Rupnik M., et al. Occurrence of toxigenic Clostridium difficile in edible bivalve molluscs. Food Microbiol 2012, 31:309-312.
4. Curry S.R., Marsh J.W., Schlackman J.L., et al. Prevalence of Clostridium difficile in uncooked ground meat products from Pittsburgh, Pennsylvania. Appl Environ Microbiol 2012, 78(12):4183-4186.
5. Tedesco F.J., Barton R.W., Alpers D.H. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974, 81:429-433.
6. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. NEngl J Med 1978, 298:531-534.
7. Mulligan M.E., Rolfe R.D., Finegold S.M., et al. Contamination of a hospital environment by Clostridium difficile. Curr Microbiol 1979, 3:173-175.
8. Kim K.H., Fekety R., Batts D.H., et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. JInfect Dis 1981, 143(1):42-50.
9. Gerding D.N., Olson M.M., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986, 146:95-100.
10. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. NEngl J Med 1989, 320(4):204-210.
11. Johnson S., Clabots C.R., Linn F.V., et al. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990, 336(8707):97-100.
12. Belmares J., Johnson S., Parada J.P., et al. MD. Molecular epidemiology of Clostridium difficile over 10 years in one tertiary care hospital. Clin Infect Dis 2009, 49:1141-1147.
13. Clabots C.R., Johnson S., Olson M.M., et al. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. JInfect Dis 1992, 166(3):561-567.
14. Shim J.K., Johnson S., Samore M.H., et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998, 351(9103):633-636.
15. Kyne L., Warny M., Qamar A., et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. NEngl J Med 2000, 342(6):390-397.
16. Samore M.H., Bettin K.M., DeGirolami P.C., et al. Wide diversity of Clostridium difficile types at a tertiary referral hospital. JInfect Dis 1994, 170:615-621.
17. Johnson S., Adelmann A., Clabots C.R., et al. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. JInfect Dis 1989, 159:340-343.
18. Figueroa I., Johnson S., Sambol S.P., et al. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 2012, 55(Suppl 2):S104-S109.
19. Eyre D.W., Babakhani F., Griffiths D., et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. JInfect Dis 2014, 209:1446-1451.
20. Johnson S., Samore M.H., Farrow K.A., et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. NEngl J Med 1999, 341:1645-1651.
21. Verity P., Wilcox M.H., Fawley W., et al. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms. JHosp Infect 2001, 49:204-209.
22. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353:2433-2441.
23. Loo V.G., Poirier L., Miller M.A., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. NEngl J Med 2005, 353:2442-2449.
24. Dallal R.M., Harbrecht B.G., Boujoukas A.J., et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002, 235:363-372.
25. See I., Mu Y., Cohen J., et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014, 58:1394-1400.
26. He M., Miyajima F., Roberts P., et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013, 45:109-113.
27. Wilcox M.H., Shetty N., Fawley W.N., et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis 2012, 55:1056-1063.
28. Health Protection Agency (United Kingdom) Quarterly epidemiological commentary: mandatory MRSA & MSSA bacteraemia, and Clostridium difficile infection data (up to July - September 2011) 2011, Health Protection Agency, London, Available at:. http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1284473407318.
29. Lucado J., Gould C., Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009 2011, HCUP statistical brief no. 124, US Department of Health and Human Services, Agency for Healthcare Research and Quality, Rockville (MD), Available at:. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf.
30. Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. NEngl J Med 2014, 370(13):1198-1208.
31. Centers for Disease Control and Prevention Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep 2012, 61:157-162.
32. Mylotte J.M., Russell S., Sackett B., et al. Surveillance for Clostridium difficile infection in nursing homes. JAm Geriatr Soc 2013, 61(1):122-125.
33. Pawar D., Tsay R., Nelson D.S., et al. Burden of Clostridium difficile infection in long-term care facilities in Monroe County, New York. Infect Control Hosp Epidemiol 2012, 33:1107-1112.
34. Centers for Disease Control and Prevention (CDC) Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1201-1205.
35. Norén T., Akerlund T., Bäck E., et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. JClin Microbiol 2004, 42:3635-3643.
36. Dial S., Delaney J.A., Barkun A.N., et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
37. McDonald L.C., Coignard B., Dubberke E., et al. Ad Hoc Clostridium difficile Surveillance Working Group. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007, 28:140-145.
38. Shears P., Prtak L., Duckworth R. Hospital-based epidemiology: a strategy for 'dealing with Clostridium difficile'. JHosp Infect 2010, 74:319-325.
39. Kutty P.K., Woods C.W., Sena A.C., et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010, 16:197-204.
40. Lambert P.J., Dyck M., Thompson L.H., et al. Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 2009, 30:945-951.
41. Khanna S., Pardi D.S., Aronson S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012, 107:89-95.
42. Lessa F.C., Mu Y., Winston L., et al. Determinants of Clostridium difficile infection incidence across diverse US geographic locations. Pediatrics 2014, 133(4):651-658. 10.1093/ofid/ofu048.
43. Chitnis A.S., Holzbauer S.M., Belflower R.M., et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013, 173:1359-1367.
44. Wilcox M.H., Mooney L., Bendall R., et al. Acase-control study of community-associated Clostridium difficile infection. JAntimicrob Chemother 2008, 62:388-396.
45. Dumyati G., Stevens V., Hannett G.E., et al. Community-associated Clostridium difficile infections, Monroe County, New York, USA. Emerg Infect Dis 2012, 18:392-400.
46. Hensgens M.P., Keessen E.C., Squire M.M., et al. European Society of Clinical Microbiology and Infectious Diseases study group for Clostridium difficile (ESGCD). Clostridium difficile infection in the community: a zoonotic disease?. Clin Microbiol Infect 2012, 18:635-645.
47. Lessa F.C. Community-associated Clostridium difficile infection: how real is it?. Anaerobe 2013, 24:121-123.
48. Eyre D.W., Walker A.S., Wyllie D., et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012, 55(Suppl 2):S77-S87.
49. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. NEngl J Med 2010, 362:197-205.
50. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
51. Hensgens M.P., Goorhuis A., Notermans D.W., et al. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro Surveill 2009, 14(45). pii (19402). Available at:. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19402.
52. Walker A.S., Eyre D.W., Wyllie D.H., et al. Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection. Clin Infect Dis 2013, 56:1589-1600.
53. Søes L.M., Holt H.M., Böttiger B., et al. The incidence and clinical symptomatology of Clostridium difficile infections in a community setting in a cohort of Danish patients attending general practice. Eur J Clin Microbiol Infect Dis 2014, 33:957-967.
54. De Almeida M.N., Heffernan H., Dervan A., et al. Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244. NZ Med J 2013, 126:9-14.
55. Lim S.K., Stuart R.L., Mackin K.E., et al. Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin Infect Dis 2014, 58:1723-1730.
56. Jury L.A., Sitzlar B., Kundrapu S., et al. Outpatient healthcare settings and transmission of Clostridium difficile. PLoS One 2013, 8:e70175.
57. Bartlett J.G. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S4-S11.
58. Pépin J., Gonzales M., Valiquette L. Risk of secondary cases of Clostridium difficile infection among household contacts of index cases. JInfect 2012, 64:387-390.
59. Limbago B., Thompson A.D., Greene S.A., et al. Development of a consensus method for culture of Clostridium difficile from meat and its use in a survey of U.S. retail meats. Food Microbiol 2012, 32:448-451.
60. Rodriguez-Palacios A., Reid-Smith R.J., Staempfli H.R., et al. Possible seasonality of Clostridium difficile in retail meat, Canada. Emerg Infect Dis 2009, 15(5):802-805.
61. Hoover D.G., Rodriguez-Palacios A. Transmission of Clostridium difficile in foods. Infect Dis Clin North Am 2013, 27:675-685.
62. Metcalf D.S., Costa M.C., Dew W.M., et al. Clostridium difficile in vegetables, Canada. Lett Appl Microbiol 2010, 51:600-602.
63. Janezic S., Zidaric V., Pardon B., et al. International Clostridium difficile animal strain collection and large diversity of animal associated strains. BMC Microbiol 2014, 14:173.
64. Kim J., Smathers S.A., Prasad P., et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008, 122:1266-1270.
65. Zilberberg M.D., Tillotson G.S., McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010, 16:604-609.
66. Wendt J.M., Cohen J.A., Mu Y., et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014, 133:651-658.
67. Kim J., Shaklee J.F., Smathers S., et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J 2012, 31:134-138.
68. Sandora T.J., Fung M., Flaherty K., et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011, 30:580-584.
69. Tai E., Richardson L.C., Townsend J., et al. Clostridium difficile infection among children with cancer. Pediatr Infect Dis J 2011, 30:610-612.
70. Tullus K., Aronsson B., Marcus S., et al. Intestinal colonization with Clostridium difficile in infants up to 18 months of age. Eur J Clin Microbiol Infect Dis 1989, 8:390-393.
71. Rousseau C., Poilane I., De Pontual L., et al. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 2012, 55:1209-1215.
72. Jangi S., Lamont J.T. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. JPediatr Gastroenterol Nutr 2010, 51:2-7.
73. Eglow R., Pothoulakis C., Itzkowitz S., et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. JClin Invest 1992, 90:822-829.
74. Stevens V., Dumyati G., Fine L.S., et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
75. Hensgens M.P., Goorhuis A., Dekkers O.M., et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. JAntimicrob Chemother 2012, 67:742-748.
76. Deshpande A., Pasupuleti V., Thota P., et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. JAntimicrob Chemother 2013, 68:1951-1961.
77. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 365:1693-1703.
78. Freedberg D.E., Salmasian H., Friedman C., et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013, 108:1794-1801.
79. Janarthanan S., Ditah I., Adler D.G., et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107:1001-1010.
80. Rogers M.A., Greene M.T., Young V.B., et al. Depression, antidepressant medications, and risk of Clostridium difficile infection. BMC Med 2013, 11:121.
81. Leung J., Burke B., Ford D., et al. Possible association between obesity and Clostridium difficile infection. Emerg Infect Dis 2013, 19:1791-1798.
82. Bishara J., Farah R., Mograbi J., et al. Obesity as a risk factor for Clostridium difficile infection. Clin Infect Dis 2013, 57:489-493.
83. Hu M.Y., Katchar K., Kyne L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterol 2009, 136:1206-1214.
84. Drekonja D.M., Amundson W.H., Decarolis D.D., et al. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med 2011, 124:1081.e1-1081.e7.
85. Bauer M.P., Hensgens M.P., Miller M.A., et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis 2012, 55(Suppl 2):S149-S153.
86. Walk S.T., Micic D., Jain R., et al. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 2012, 55:1661-1668.
87. Vardakas K.Z., Konstantelias A.A., Loizidis G., et al. Risk factors for development of Clostridium difficile infection due to BI/NAP1/027 strain: a meta-analysis. Int J Infect Dis 2012, 16:e768-e773.